2 research outputs found
Chikungunya vaccines: advances in the development and prospects for marketing approval
Chikungunya fever is an acute infectious disease caused by the mosquito-borne Chikungunya virus (CHIKV). In the last decades, cases of the disease have been reported in more than 100 countries; therefore, CHIKV presents a global public health problem. CHIKV genotypes have limited antigenic diversity, and documented reinfection is very rare. Hence, a vaccine could prevent infection and potential disability, as well as reduce the epidemic spread of CHIKV in the population.The aim of the study was to review approaches to the development of preventive vaccines against CHIKV, evaluate promising vaccine candidates in preclinical or clinical development stages, and analyse perspectives and challenges of bringing these vaccines to the pharmaceutical market.According to the literature reviewed, both traditional and modern platforms are used in the development of CHIKV vaccines, which has been ongoing for several decades. Each platform has its advantages and limitations. The most popular platforms are live attenuated vaccines and vaccines with viral vector constructs. To date, about 25 vaccine candidates have successfully passed through preclinical studies, and more than 7 vaccine candidates have progressed to various phases of clinical studies. The preventive medicinal products that have reached the clinical development stage include 4 live attenuated vaccines, 1 inactivated vaccine, 1 vaccine containing virus-like particles, and 1 mRNA vaccine. All 7 candidates have demonstrated cross-protection against multiple genotypes of CHIKV at the level of either preclinical in vivo studies and/or clinical in vitro studies. The research continues, and this shows that not only the scientific community but also health systems are interested in bringing effective CHIKV vaccines to the pharmaceutical market
ΠΡΠΎΠ³ΡΠ΅ΡΡ Π² ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ΅ Π²Π°ΠΊΡΠΈΠ½ Π΄Π»Ρ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ Π»ΠΈΡ ΠΎΡΠ°Π΄ΠΊΠΈ Π§ΠΈΠΊΡΠ½Π³ΡΠ½ΡΡ ΠΈΒ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π½Π° ΡΡΠ½ΠΊΠ΅
Chikungunya fever is an acute infectious disease caused by the mosquito-borne Chikungunya virus (CHIKV). In the last decades, cases of the disease have been reported in more than 100 countries; therefore, CHIKV presents a global public health problem. CHIKV genotypes have limited antigenic diversity, and documented reinfection is very rare. Hence, a vaccine could prevent infection and potential disability, as well as reduce the epidemic spread of CHIKV in the population.The aim of the study was to review approaches to the development of preventive vaccines against CHIKV, evaluate promising vaccine candidates in preclinical or clinical development stages, and analyse perspectives and challenges of bringing these vaccines to the pharmaceutical market.According to the literature reviewed, both traditional and modern platforms are used in the development of CHIKV vaccines, which has been ongoing for several decades. Each platform has its advantages and limitations. The most popular platforms are live attenuated vaccines and vaccines with viral vector constructs. To date, about 25 vaccine candidates have successfully passed through preclinical studies, and more than 7 vaccine candidates have progressed to various phases of clinical studies. The preventive medicinal products that have reached the clinical development stage include 4 live attenuated vaccines, 1 inactivated vaccine, 1 vaccine containing virus-like particles, and 1 mRNA vaccine. All 7 candidates have demonstrated cross-protection against multiple genotypes of CHIKV at the level of either preclinical in vivo studies and/or clinical in vitro studies. The research continues, and this shows that not only the scientific community but also health systems are interested in bringing effective CHIKV vaccines to the pharmaceutical market.ΠΠΈΡ
ΠΎΡΠ°Π΄ΠΊΠ° Π§ΠΈΠΊΡΠ½Π³ΡΠ½ΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ ΠΎΡΡΡΠΎΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, ΠΊΠΎΡΠΎΡΠΎΠ΅ Π²ΡΠ·ΡΠ²Π°Π΅ΡΡΡ Π²ΠΈΡΡΡΠΎΠΌ Π§ΠΈΠΊΡΠ½Π³ΡΠ½ΡΡ (Π§ΠΠΠ) ΠΈ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½ΡΠ΅ΡΡΡ ΠΊΠΎΠΌΠ°ΡΠ°ΠΌΠΈ. Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΡ ΡΡΠ° ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Π° Π² Π±ΠΎΠ»Π΅Π΅ ΡΠ΅ΠΌ 100 ΡΡΡΠ°Π½Π°Ρ
ΠΈ ΠΏΡΠ΅Π²ΡΠ°ΡΠΈΠ»Π°ΡΡ Π² Π³Π»ΠΎΠ±Π°Π»ΡΠ½ΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π΄Π»Ρ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΠ΅ΠΌ ΡΡΠΎ Π°Π½ΡΠΈΠ³Π΅Π½Π½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ Π³Π΅Π½ΠΎΡΠΈΠΏΠ°ΠΌΠΈ Π§ΠΠΠ Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½Ρ ΠΈ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΠ΅ ΡΠ»ΡΡΠ°ΠΈ ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ ΡΠ΅Π³ΠΈΡΡΡΠΈΡΡΡΡ, Π²Π°ΠΊΡΠΈΠ½Π° ΠΌΠΎΠ³Π»Π° Π±Ρ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΠΏΡΠ΅Π΄ΠΎΡΠ²ΡΠ°ΡΠΈΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ ΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΡ ΠΏΠΎΡΠ΅ΡΡ ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ, Π½ΠΎ ΠΈ ΡΠΌΠ΅Π½ΡΡΠΈΡΡ ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ Π§ΠΠΠ ΡΡΠ΅Π΄ΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ.Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ β Π°Π½Π°Π»ΠΈΠ· Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π²Π°ΠΊΡΠΈΠ½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π΄Π»Ρ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ Π»ΠΈΡ
ΠΎΡΠ°Π΄ΠΊΠΈ Π§ΠΈΠΊΡΠ½Π³ΡΠ½ΡΡ, ΠΎΡΠ΅Π½ΠΊΠ° ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², Π²ΡΡΠ΅Π΄ΡΠΈΡ
Π½Π° ΡΡΠ°ΠΏΡ Π΄ΠΎΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
(ΠΠΠ) ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ (ΠΠ), Π° ΡΠ°ΠΊΠΆΠ΅ Π°Π½Π°Π»ΠΈΠ· ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ² ΠΈ ΠΏΡΠΎΠ±Π»Π΅ΠΌ Π²ΡΠ²ΠΎΠ΄Π° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π½Π° ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΠ½ΠΎΠΊ.ΠΠ½Π°Π»ΠΈΠ· Π½Π°ΡΡΠ½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΠΎΠΊΠ°Π·Π°Π», ΡΡΠΎ ΠΏΡΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ΅ Π²Π°ΠΊΡΠΈΠ½, ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°ΡΡΠ΅ΠΉΡΡ ΡΠΆΠ΅ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΠΉ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ ΠΊΠ°ΠΊ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΠ΅, ΡΠ°ΠΊ ΠΈ Π½ΠΎΠ²Π΅ΠΉΡΠΈΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠ»Π°ΡΡΠΎΡΠΌΡ. ΠΠ°ΠΆΠ΄Π°Ρ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΏΠ»Π°ΡΡΠΎΡΠΌΠ° ΠΈΠΌΠ΅Π΅Ρ ΡΠ²ΠΎΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΈ ΠΈ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π°. ΠΠ° Π΄Π°Π½Π½ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ ΠΎΠΊΠΎΠ»ΠΎ 25 ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΎΠΊ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΡΡΠΏΠ΅ΡΠ½ΠΎ ΠΏΡΠΎΡΠ»ΠΈ ΡΡΠ°ΠΏ ΠΠΠ ΠΈ Π±ΠΎΠ»Π΅Π΅ 7 Π½Π°Ρ
ΠΎΠ΄ΡΡΡΡ Π½Π° ΡΠ°Π·Π½ΡΡ
ΡΡΠ°Π΄ΠΈΡΡ
ΠΠ. Π‘Π°ΠΌΡΠΌΠΈ ΠΏΠΎΠΏΡΠ»ΡΡΠ½ΡΠΌΠΈ ΡΠ²Π»ΡΡΡΡΡ ΠΏΠ»Π°ΡΡΠΎΡΠΌΠ° ΠΆΠΈΠ²ΡΡ
Π°ΡΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π²Π°ΠΊΡΠΈΠ½, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠ»Π°ΡΡΠΎΡΠΌΠ° Π²Π°ΠΊΡΠΈΠ½ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π²Π΅ΠΊΡΠΎΡΠ½ΡΡ
ΠΊΠΎΠ½ΡΡΡΡΠΊΡΠΈΠΉ. ΠΡΠ΅ΠΏΠ°ΡΠ°ΡΡ, Π½Π°Ρ
ΠΎΠ΄ΡΡΠΈΠ΅ΡΡ Π² ΡΠ°Π·Π½ΡΡ
ΡΠ°Π·Π°Ρ
ΠΠ, ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΠΆΠΈΠ²ΡΠΌΠΈ Π°ΡΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Π²Π°ΠΊΡΠΈΠ½Π°ΠΌΠΈ (ΡΠ΅ΡΡΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°), ΠΈΠ½Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ (ΠΎΠ΄ΠΈΠ½ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ), ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠΌ Π²ΠΈΡΡΡΠΎΠΏΠΎΠ΄ΠΎΠ±Π½ΡΠ΅ ΡΠ°ΡΡΠΈΡΡ (ΠΎΠ΄ΠΈΠ½ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ) ΠΈ ΡΠΎΠ·Π΄Π°Π½Π½ΡΠΌ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΌΠ ΠΠ (ΠΎΠ΄ΠΈΠ½ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ). ΠΠ»Ρ Π²ΡΠ΅Ρ
ΡΠ΅ΠΌΠΈ Π²Π°ΠΊΡΠΈΠ½ Π±ΡΠ»Π° ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Π° ΠΏΠ΅ΡΠ΅ΠΊΡΠ΅ΡΡΠ½Π°Ρ Π·Π°ΡΠΈΡΠ° ΠΎΡ ΡΡΠ°ΠΌΠΌΠΎΠ² Π§ΠΠΠ ΡΠ°Π·Π½ΡΡ
Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΈΠ»ΠΈ Π½Π° ΡΡΠ°Π΄ΠΈΠΈ ΠΠΠ in vivo ΠΈ/ΠΈΠ»ΠΈ Π½Π° ΡΡΠ°Π΄ΠΈΠΈ ΠΠ in vitro. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°ΡΡΡΡ, ΡΡΠΎ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π΅Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π½Π°ΡΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠ΅ΡΠ΅ΡΠ°, Π½ΠΎ ΡΠ°ΠΊΠΆΠ΅ ΠΎΠΆΠΈΠ΄Π°Π½ΠΈΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ ΠΊ Π²ΡΠ²ΠΎΠ΄Ρ Π½Π° ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΠ½ΠΎΠΊ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
Π²Π°ΠΊΡΠΈΠ½ ΠΏΡΠΎΡΠΈΠ² Π»ΠΈΡ
ΠΎΡΠ°Π΄ΠΊΠΈ Π§ΠΈΠΊΡΠ½Π³ΡΠ½ΡΡ